Literature DB >> 14706828

Cytokines regulate the affinity of soluble CD44 for hyaluronan.

Joanna Cichy1, Ellen Puré.   

Abstract

CD44, a receptor for the extracellular matrix glycosaminoglycan hyaluronan, has been implicated in many adhesion-dependent cellular processes including tumor growth and metastasis. Soluble CD44 has been identified in the serum of normal individuals. Furthermore, tumor progression is often associated with marked increases in plasma levels of soluble CD44. Release of soluble CD44 by proteolytic cleavage (shedding) of membrane-anchored CD44 is likely to alter cellular responses to the environment due to modification of the cell surface and the potential for soluble CD44 to influence CD44-mediated hyaluronan binding to cell surfaces. Cellular activation is typically required to induce hyaluronan binding to cell surface CD44 but the affinity of endogenous soluble CD44 for hyaluronan remains unknown. In this study, we demonstrate that oncostatin M and transforming growth factor beta1 (TGF-beta1) which stimulate hyaluronan binding to HTB58 lung epithelial-derived tumor cells, also induce the release of soluble CD44. Interestingly, soluble CD44 released by oncostatin M-treated cells retained the ligand-binding properties of the membrane-anchored receptor. In contrast, soluble CD44 released from TGF-beta1-treated HTB58 cells differed in its hyaluronan-binding capacity from cell surface CD44 expressed on TGF-beta1-stimulated cells. These data indicate that the mechanisms that regulate the generation of soluble CD44 may also govern the binding of the released receptor to hyaluronan and therefore determine the impact on CD44-dependent physiologic and pathologic processes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706828     DOI: 10.1016/s0014-5793(03)01370-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  9 in total

Review 1.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

Review 2.  The CD44-HA axis and inflammation in atherosclerosis: A temporal perspective.

Authors:  Mia Krolikoski; James Monslow; Ellen Puré
Journal:  Matrix Biol       Date:  2018-05-21       Impact factor: 11.583

3.  Identification of specific chondroitin sulfate species in cutaneous autoimmune disease.

Authors:  Jessica S Kim; Victoria P Werth
Journal:  J Histochem Cytochem       Date:  2011-08       Impact factor: 2.479

Review 4.  Hyaluronan and Its Receptors: Key Mediators of Immune Cell Entry and Trafficking in the Lymphatic System.

Authors:  Louise A Johnson; David G Jackson
Journal:  Cells       Date:  2021-08-12       Impact factor: 6.600

5.  sCD44 internalization in human trabecular meshwork cells.

Authors:  Michael J Nolan; Tomoyo Koga; Loyal Walker; Ryan McCarty; Algis Grybauskas; Michael C Giovingo; Kevin Skuran; Paulius V Kuprys; Paul A Knepper
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

6.  Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I.

Authors:  Lili Gao; Limei Yan; Bei Lin; Jian Gao; Xiuyun Liang; Yanyan Wang; Juanjuan Liu; Shulan Zhang; Masao Iwamori
Journal:  J Exp Clin Cancer Res       Date:  2011-02-07

Review 7.  CD44 and Tumor-Derived Extracellular Vesicles (TEVs). Possible Gateway to Cancer Metastasis.

Authors:  Rafał Szatanek; Monika Baj-Krzyworzeka
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

8.  Hyaluronidase and pH Dual-Responsive Nanoparticles for Targeted Breast Cancer Stem Cells.

Authors:  Weinan Li; Xiaoyu Zhang; Yang Nan; Li Jia; Jialin Sun; Lina Zhang; Yanhong Wang
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

Review 9.  CD44 Glycosylation as a Therapeutic Target in Oncology.

Authors:  Chengcheng Liao; Qian Wang; Jiaxing An; Jie Chen; Xiaolan Li; Qian Long; Linlin Xiao; Xiaoyan Guan; Jianguo Liu
Journal:  Front Oncol       Date:  2022-07-21       Impact factor: 5.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.